ÌìÃÀ´«Ã½

Cary Gross, MD

Cary Gross, MD

Yale Cancer Center/Smilow Cancer Hospital

Professor of Medicine (General Medicine) and of Epidemiology (Chronic Diseases); Founder and Director, Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, Yale School of Medicine

Expertise: Chronic DiseasesChronic DiseasesEpidemiologyEpidemiology

Dr. Cary Gross is a Professor of Medicine and Public Health, and Director of the National Clinician Scholars Program at Yale. Dr. Gross completed his residency in Internal Medicine at New York Hospital-Cornell Medical Center and served as chief medical resident at Memorial Sloan-Kettering Cancer Center the following year. His research addresses comparative effectiveness, quality, and health equity, with a focus on cancer prevention and treatment. He aims to use real-world research to generate knowledge that will inform change in clinical care and health policy. He is a founding Director of Yale’s Cancer Outcomes Public Policy and Effectiveness Research Center (COPPER). His research has been supported by the National Cancer Institute, the American Cancer Society, among others. As a former Robert Wood Johnson Foundation Clinical Scholar, Dr. Gross has advanced training in biostatistics, epidemiology, research ethics, and outcomes research. Follow him on twitter: @cpgYale

No Clipping

No Research/Citations

Study Reveals Disparities in Colorectal Cancer Screening

Significantly more younger people underwent colorectal cancer screening after the recommended age to begin such screening was lowered, Yale researchers report. In a new study of 10 million insured people aged 45 to 49, researchers found that a recommendation by the United States Preventative Services Task Force to drop the age for starting colorectal cancer screening by five years to age 45 was highly effective — tripling the rate of screening overall — but the magnitude of increase was significantly smaller for low-income and rural populations.
03-Oct-2024 11:05:23 AM EDT

Is comprehensive genetic testing worth it for patients with cancer?

Comprehensive gene panel testing, one of the exciting new tools in cancer diagnostics, warrants greater scrutiny — as does a federal program aimed at speeding up the review process for proposed new medical technologies. Those are conclusions of Yale medical experts who studied both and published a report in the Journal of the National Cancer Institute on Sept.
24-Sep-2024 12:05:49 PM EDT

New Yale Study Suggests Breast Cancer Screening for Older Women Carries Risks

Breast cancer screening for women over 70 is not without risks, according to new research from Yale School of Medicine’s COPPER Center. Although some guidelines recommend continuing screening for older women, a new study emphasizes the importance of assessing potential harms associated with testing, such as overdiagnosis, which, researchers say, can negatively affect quality of life.
08-Aug-2023 10:00:59 AM EDT

How Incarceration Raises Risk of Cancer Diagnosis and Death—Even After Release

In 2012, Michael Cruz exercised a lot. Four years into a 15-year prison sentence, this was one of the only things he had, he says, until he noticed a numb, tingling sensation in one of his toes while working out. At first, he dismissed the feeling. But it persisted, and over time, spread up his ankle. Then, he began experiencing little sharp pains in his back, which he attributed to muscle spasms from his workouts.
20-Mar-2023 04:45:53 PM EDT

No Quotes

Available for logged-in users onlyLogin HereorRegister

No Video

close
0.07977